Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform generates customized innate cell engagers (ICE®), bispecific antibodies, which target innate immune cells to destroy tumor cells. The broad pipeline enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. It comprises wholly owned and partnered programs and builds on monotherapy or combination approaches with Natural Killer (NK) cell products or other I-O therapeutics. The lead candidate AFM13 is in development for patients with CD30+ lymphomas. It has been studied as monotherapy, in combination with NK cells, and in combination with a PD-1 inhibitor. Affimed’s new phase 2 study, LuminICE-203will investigate AFM13 in combination with AlloNK® (also known as AB-101), an off-the-shelf, allogeneic NK cell from Artiva Biotherapeutics, in patients with relapsed or refractory (r/r) classical Hodgkin lymphoma with an exploratory arm in patients with r/r/ peripheral T cell lymphoma. AFM24 is specific for EGFR and CD16A and targets solid tumors. Based on the data generated to date, the developmental focus of AFM24 is in combination with the anti-PD-L1 inhibitor atezolizumab. AFM28 is being developed for patients with CD123-expressing hematological malignancies, including acute myeloid leukemia (AML), in need of new therapeutic options. A first-in-human Phase 1 clinical study was initiated in 2023 and development in combination with allogeneic NK cell therapy is planned.